The TAIL-PrEP Study
ConditionHIV Infections
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorColumbia University
About this trial
The goal of the TAIL-PrEP study is to understand how to support the safe discontinuation of injectable long-acting cabotegravir (cab-LA) and lenacapavir (LEN) while maximizing the public health impact of biomedical HIV prevention interventions. In Aim 1, the study will pilot test and assess the acceptability and feasibility of the TAIL-PrEP intervention: for participants discontinuing cab-LA, this will consist of monthly cabotegravir drug level monitoring to provide personalized HIV prevention coaching, for participants considering discontinuing cab-LA or LEN, this will consist of a one-time personalized HIV prevention coaching session. In Aim 2, the study will refine the TAIL-PrEP intervention and implementation strategy based on findings from the pilot study.
Eligibility criteria
Qualifiers
At least 18 years of age
HIV-negative (self-report)
Able to speak and read in English
Have access to an internet-connected device capable of running the online video conferencing platform
Disqualifiers
None
Trial design
Treatments tested in this trial
- TAIL-PrEP for patients discontinuing cab-LA
- TAIL-PrEP for patients considering discontinuing cab-LA
- TAIL-PrEP for patients considering discontinuing LEN
Treatment groups
30 Participants
are divided into 3 treatment groupsSponsors and collaborators
Columbia University
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
Source ClinicalTrials.gov